FIGURE

Fig. 3

ID

ZDB-FIG-220719-63

Publication

Bär et al., 2022 - Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

Other Figures

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

All Figure Page

Back to All Figure Page

Fig. 3

LDH release by liver cancer cell lines HepG2 and Huh7 and the non-transformed hepatocyte cell line AML12 into the media after 24 h treatment with broxbam in different concentrations. Data are presented as the LDH release relative to those in untreated controls, where basal LDH release was set to 0%. Values are presented as the mean ± SEM. n=4. LDH, lactate dehydrogenase; ctrl, control.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Oncol.